Omnicell, Inc OMCL
We take great care to ensure that the data presented and summarized in this overview for OMNICELL, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OMCL
View all-
Black Rock Inc. New York, NY8.18MShares$377 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.53MShares$255 Million0.0% of portfolio
-
State Street Corp Boston, MA2.27MShares$104 Million0.0% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.55MShares$71.2 Million0.43% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.25MShares$57.4 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.25MShares$57.4 Million0.13% of portfolio
-
Victory Capital Management Inc1.15MShares$52.8 Million0.05% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.14MShares$52.5 Million0.71% of portfolio
-
Macquarie Group LTD Australia, C31.12MShares$51.5 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA1.1MShares$50.8 Million0.0% of portfolio
Latest Institutional Activity in OMCL
Top Purchases
Top Sells
About OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Insider Transactions at OMCL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 10
2024
|
Mark W Parrish |
SELL
Open market or private sale
|
Direct |
12,000
-17.04%
|
$564,000
$47.3 P/Share
|
Nov 15
2024
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-0.46%
|
$10,125
$45.67 P/Share
|
Nov 15
2024
|
Nnamdi Njoku EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,520
+50.0%
|
-
|
Nov 15
2024
|
Nchacha Etta EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
593
-0.8%
|
$26,685
$45.67 P/Share
|
Nov 15
2024
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-0.7%
|
$51,975
$45.67 P/Share
|
Sep 15
2024
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.14%
|
$3,053
$43.16 P/Share
|
Aug 15
2024
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,043
-3.54%
|
$253,806
$42.93 P/Share
|
Aug 15
2024
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,354
-2.66%
|
$56,868
$42.93 P/Share
|
Aug 15
2024
|
Brian H. Nutt VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,647
+40.26%
|
-
|
Aug 15
2024
|
Nchacha Etta EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,830
-3.67%
|
$118,860
$42.93 P/Share
|
Jun 15
2024
|
Corey J Manley EVP&CHIEF LEGAL/ADMIN OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
221
-0.43%
|
$5,967
$27.91 P/Share
|
Jun 15
2024
|
Randall A Lipps CHAIRMAN, PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,599
-1.24%
|
$70,173
$27.91 P/Share
|
May 21
2024
|
Mark W Parrish |
BUY
Grant, award, or other acquisition
|
Direct |
6,143
+8.02%
|
-
|
May 21
2024
|
Edward Peter Bousa |
BUY
Grant, award, or other acquisition
|
Direct |
5,802
+33.53%
|
-
|
May 21
2024
|
Mary Garrett |
BUY
Grant, award, or other acquisition
|
Direct |
6,058
+37.51%
|
-
|
May 21
2024
|
Eileen J. Voynick |
BUY
Grant, award, or other acquisition
|
Direct |
6,058
+41.66%
|
-
|
May 21
2024
|
Bruce E Scott |
BUY
Grant, award, or other acquisition
|
Direct |
6,177
+27.71%
|
-
|
May 21
2024
|
Joanne B Bauer |
BUY
Grant, award, or other acquisition
|
Direct |
6,741
+15.13%
|
-
|
May 21
2024
|
Kaushik Ghoshal |
BUY
Grant, award, or other acquisition
|
Direct |
5,717
+41.32%
|
-
|
May 21
2024
|
Robin Gene Seim |
BUY
Grant, award, or other acquisition
|
Direct |
6,143
+13.16%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 292K shares |
---|
Payment of exercise price or tax liability | 15.5K shares |
---|---|
Open market or private sale | 12K shares |